ABSTRACT

Heparin, including unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and heparin derivatives, are commonly used in venous thromboembolism treatment and reportedly have beneficial effects on cancer survival. Heparin can affect the proliferation, adhesion, angiogenesis, migration and invasion of cancer cells via multiple mechanisms. The main mechanisms involve inhibition of heparanase, P-/L-selectin, angiogenesis, and interference with the CXCL12-CXCR4 axis. Here we summarize the current experimental evidence regarding the anti-cancer role of heparin and its derivatives, and conclude that there is evidence to support heparin’s role in inhibiting cancer progression, making it a promising anti-cancer agent.

摘要

肝素，包括普通肝素（UFH），低分子量肝素（LMWH）和肝素衍生物，通常用于静脉血栓栓塞治疗，据报道对癌症生存具有有益作用。肝素可以通过多种机制影响癌细胞的增殖，粘附，血管生成，迁移和侵袭。主要机制包括抑制乙​​酰肝素酶，P- / L-选择蛋白，血管生成和干扰CXCL12-CXCR4轴。在这里，我们总结了有关肝素及其衍生物的抗癌作用的当前实验证据，并得出结论，有证据支持肝素在抑制癌症进展中的作用，使其成为有希望的抗癌药。